BTVPUR AlSap 2-4
inactivated adjuvanted vaccine against bluetongue virus serotype 2 and 4 infections
Table of contents
Overview
The marketing authorisation for this product has been withdrawn due to the application of the sunset clause.
Authorisation details
| Product details | |
|---|---|
| Name |
BTVPUR AlSap 2-4
|
| Agency product number |
EMEA/V/C/000139
|
| Active substance |
|
| International non-proprietary name (INN) or common name |
inactivated adjuvanted vaccine against bluetongue virus serotype 2 and 4 infections
|
| Species |
Sheep
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI04AA02
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Mérial
|
| Revision |
4
|
| Date of issue of marketing authorisation valid throughout the European Union |
04/11/2010
|
| Contact address |
29 avenue Tony Garnier |
Product information
01/06/2018 BTVPUR AlSap 2-4 - EMEA/V/C/000139 - R/0006
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
bluetongue virus
-
Inactivated viral vaccines
-
Immunologicals for ovidae
Therapeutic indication
Active immunisation of sheep to prevent viraemia and to reduce clinical signs caused by bluetongue virus serotypes 2 and 4.